Nebenwirkungen · Xeloda
Xeloda 150 mg film-coated tablets. Xeloda 500 mg film-coated tablets. · Abschnitt 4.8 · PDF-Seite 18
HOS-091456 · Präparat HOS-084311
The results of a meta-analysis of 14 clinical trials with data from over 4700 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhoea: increasing capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender. The following covariates were statistically significantly associated with a decreased risk of developing diarrhoea: increasing cumulative capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T14:45:00Z · SHA-256 632b962270222a1b1c9626101f7ef2fdc0c5500039de7f68bd6fd6e7e22b7b52 · Passage 69bdc4007aee91e8d601af5669f93cb964f6194b68c5e4296adce451ce5c23de · Zeichen 21757–22404 im Abschnitt